Venn Life Sciences Share Discussion Threads

[rivaldo] 01/11/2017 11:50

Let's hope so Prof. And a £5,700 buy has just caused a 0.375p jump, so stock is presumably still hard to find.

[professor x] 01/11/2017 10:37

This bodes well Riv. It's also the first time in quite a while we have made a new closing high (short term however). Turning point maybe?

[rivaldo] 31/10/2017 15:35

Two buys today - and the price has moved up on each one even though they only total £1,600 :o))

[chadders] 27/10/2017 12:41

Let's hope the rally doesn't fizzle out as quickly as the last time. Good to see though.

[rivaldo] 27/10/2017 09:56

A 50k buy at 13.8p has moved the price forward nicely this morning.

[gleach23] 09/10/2017 16:20

I think it was a sell rivaldo. The online Bid rose to 14.01 and then dropped back to 13.78. I suspected a trade must have gone through and this 79k was then reported an hour later.

[rivaldo] 09/10/2017 15:59

I suspect the 79k at 14.01p just reported is actually a Buy from earlier today which helped precipitate the rise.

[basem1] 09/10/2017 13:23

What price do we need to get to to break the downtrend. 16/17p ?? We're not out of the woods just yet

[basem1] 09/10/2017 13:19

That was my 10000 guys. Had to go NT for a max 10000.

[rivaldo] 09/10/2017 13:17

Indeed - just moved up another 0.38p on a single £1,400 buy :o))

Could be quite a dramatic rise in store if there's now such a shortage of stock.

[gleach23] 09/10/2017 12:32

think you might be right rivaldo...after that 14k buy just now there isn't even 10 shares available to buy online once again

edit - the underlying online Bid price has moved from 13.13 to 13.33 since that buy too

[rivaldo] 09/10/2017 11:44

Moving up again - delayed buy trades to be reported later?

[gleach23] 04/10/2017 18:42

Nice 155k buy @ 13.25 posted after the bell bodes well for tomorrow

[gleach23] 04/10/2017 16:07

Can't even buy 10 shares online at the moment with market quote @ 13.50 on the Offer

[gleach23] 04/10/2017 15:36

While I could sell my entire modest holding on a dummy trade, I noticed there were only 25k left to buy @ 12.995 so I took them. This seemed to shift the online Bid from 12.56 to the current 12.80.

After GHF's larger purchases, the fact that a 25k purchase shifted the Bid in this way hopefully signals that the share price is ready to move up again on relatively light volume, with 15p being first base.

[che7win] 04/10/2017 15:18

Nicely bottomed out now IMHO.

[chadders] 04/10/2017 15:15

Nice to see a bit of volume. 13p now being paid. Are we due any news?

[rivaldo] 04/10/2017 09:33

Nice 100,000 buy just now at 12.95p, almost the full 13p offer price.

[rivaldo] 03/10/2017 14:04

Cheers GHF, appreciated.

[yump] 01/10/2017 18:56

Thanks got that. I'm a bit underwater here as prematurely guessed the bottom !

[glasshalfull] 01/10/2017 18:02

rivaldo/yump - Sent you both a message.

Kind regards,
GHF

[yump] 01/10/2017 17:33

ghf

What do you make of the general radio silence from Venn ?

[rivaldo] 01/10/2017 16:01

GHF, great to see you buying in here - a very good sign! I agree with your summary, and would also point out that being based in Dublin makes VENN very attractive from a post-Brexit standpoint in providing an instant entrée to the European pharma/medical market.

Interesting new interview here with a VENN operations manager re their clinical trial expertise:



Extracts:

"Q&A: talking investigator initiated trials with Venn Life Sciences
by Dave Gray
28 September 2017

Behind every great medical device, there’s a great clinical trial. MTI editor Dave Gray spoke to Colette Donaghy, clinical operations manager, Venn Life Sciences, to find out what goes into making a device trial successful."

"Yet despite these challenges, Donaghy says that Venn continues to attract innovators from around the globe. In fact, the group recently collaborated in a clinical trial in cardiology which turned out to be one of the largest investigator-lead studies in disease of the left main artery being conducted anywhere in the world.

The project began when Venn’s COO was approached by one of two lead investigators, Professor Robert-jan van Geuns at the Erasmus University in the Netherlands. Both he and Professor Keith Oldroyd who is based in the Golden Jubilee Hospital in Glasgow realised at a very early stage that they needed help to conduct this large-scale investigator initiated study....

.....The first challenge was the administrative task of setting up the study in different countries. To do that requires knowledge of the regulatory pathways in each country.

Venn has experts around the world capable of undertaking this kind of work.

Donaghy says that this specialist knowledge is invaluable when trying to conduct trials on an international scale. “In each country we had to go through the relevant ethical review bodies, who looked at the study, checked that they were happy for it to be conducted, and that there would be no negative impact for the patient.”

The other challenge for the client was setting up contracts. Venn needed to set up a contract with each institution, and in some cases with each investigator. The group uses a corporate legal adviser, which is essential in securing an agreement which protects both Venn, and the client.

“There’s a lot to do when setting up an international clinical trial. Each country needs to be set up individually and the sites trained in the study processes. And if that’s going to be happening in different countries, then you need people who can speak the language.” Venn has sites in Russia, Poland, Germany, France, the Netherlands and the UK.

The trial is ongoing, and Donaghy says that there is significant interest from clinicians in the eventual findings and the primary outcomes at 24 months.

“This study will be followed up for the next five years. We will monitor major adverse coronary events and they’ll be classed into categories – e.g. bleeding, thrombosis, stent replacement, etc. We will monitor this over a period of five years, allowing us to look back and see why those things happened.

“Currently the client is highly satisfied that we delivered the trial within the timelines that we were given, and that we managed to get full recruitment. This is one of the largest investigator-lead studies in this area that is being conducted anywhere in the world.”

[glasshalfull] 29/9/2017 16:23

rivaldo - I note this morning's acquisition by Ergomed of PSR, "an international niche contract research organisation". They're paying €5.7m for a business with €4.7m of annual revenues and €0.34m EBITDA.

VENN are forecast to make €18.5m revenues this year, with €0.9m EBITDA.

On a PSR basis, this would value VENN at around €22.5m. On an EBITDA basis this would value VENN at around €15m.

This compares to VENN's current m/cap of €8.6m.

- - - - - -

Appreciate you highlighting Rivaldo. PSR are a far smaller CRO & goes to show the lowly valuation VENN are currently on.

I've been picking up stock recently - & some more today - as I envisage that Private Equity or competitor may soon cast their eyes in this direction & determine that they could offer a decent premium & still acquire VENN on a fairly low multiple of turnover or EBITDA.

As you've pointed out, VENN are forecast to deliver €18.5m turnover this year & had turnover of €18m last year which is a respectable size business that a bidder may see as an opportunity to build economies of scale with an existing business, or perhaps build a business around it in terms of Private Equity initiating a buy/build model.

VENN's share price is down 50% in the last 12 months & market cap £7.6m with EV of £5.0m.

I reckon something will give in the next 6/12 months!

Kind regards,
GHF

[rivaldo] 28/9/2017 09:50

There's life - a 100,000 buy at 12.41p has caused a tick up.

I note this morning's acquisition by Ergomed of PSR, "an international niche contract research organisation". They're paying €5.7m for a business with €4.7m of annual revenues and €0.34m EBITDA.

VENN are forecast to make €18.5m revenues this year, with €0.9m EBITDA.

On a PSR basis, this would value VENN at around €22.5m. On an EBITDA basis this would value VENN at around €15m.

This compares to VENN's current m/cap of €8.6m.